-- 由於美國總統川普宣布黎巴嫩和以色列同意停火10天,提振了市場對中東和平前景的樂觀情緒,美國基準股指盤中走高。 週四午盤過後,那斯達克指數上漲0.4%,至24,100.4點;標普500指數上漲0.2%,至7037.9點。兩大股指前一交易日均創下歷史新高。道瓊工業指數週四盤中上漲0.1%,至48528.2點。 各板塊中,能源板塊領漲,而醫療保健板塊跌幅最大。 川普週四表示,黎巴嫩和以色列之間的停火將於美國東部時間下午5點生效。 川普在社交媒體上發文稱:“我將邀請以色列總理內塔尼亞胡和黎巴嫩總統奧恩前往白宮,舉行自1983年以來以色列和黎巴嫩之間的首次實質性會談。雙方都希望實現和平,我相信和平會很快到來。” 根據美國有線電視新聞網(CNN)報道,黎巴嫩總理納瓦夫·薩拉姆對川普的聲明表示歡迎,該聲明旨在暫停以色列與伊朗支持的黎巴嫩真主黨之間的敵對行動。 CNN引述真主黨高級議員易卜拉欣·穆薩維的話報道稱,如果以色列停止襲擊,真主黨將遵守停火協議。 西德州中質原油(WTI)盤中上漲4.4%,至每桶95.29美元;布蘭特原油上漲5.1%,至每桶99.76美元。 「由於市場懷疑霍爾木茲海峽的緊張局勢能否很快緩解,油價上漲,」D.A. Davidson在一份報告中表示。 彭博新聞週四引述熟悉此事的阿拉伯海灣國家和歐洲官員的話報道稱,美國和伊朗達成和平協議大約需要六個月時間,雙方應延長停火期限以涵蓋這段時間。 美國公債殖利率盤中走高,10年期公債殖利率上漲3個基點至4.31%,2年期公債殖利率上漲1個基點至3.77%。 公司方面,IBM(IBM)股價上漲2.4%,成為道瓊指數中漲幅第二大的股票。奧本海默在一份報告中表示,由於軟體業務的強勁成長勢頭以及對Confluent收購案的提前完成,這家科技巨頭第一季的業績可能超出華爾街的預期,並上調營收預期。 雅培公司 (ABT) 股價下跌 6.8%,成為標普 500 指數中跌幅最大的股票。此前,這家醫療保健公司下調了全年盈利預期,以反映收購癌症診斷公司 Exact Sciences 的影響。 嘉信理財 (SCHW) 緊隨雅培之後,在標普 500 指數中下跌 6%。這家金融服務提供商的第一季業績年增,客戶資產激增,但營收低於華爾街預期。 經濟新聞方面,聯準會數據顯示,美國 3 月工業生產意外下降。 牛津經濟研究院在一份報告中指出,現在就將此次下降歸咎於中東衝突還為時過早,此次下降是由採礦和公用事業部門的產出「急劇下降」所致。 黃金價格下跌 0.3%,至每盎司 4,807.10 美元;白銀價格下跌 1.6%,至每盎司 78.38 美元。
Related Articles
Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.
Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Baker Hughes
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $14 to $82, reflecting a combination of our sum-of-the-parts (SOTP) and DCF models. For our SOTP model, we presume the oilfield services business (about 50% of BKR's franchise) to be valued at about 10x projected 2027 EBITDA (in line with major peers) and its industrial energy technology business (the other 50%) valued at 14x projected 2027 EBITDA (in line with the peer median). This blended approach, yielding a 12x multiple, implies a value of $73 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5% per year, terminal growth of 2.5%, discounted at a WACC of 6.3%, yields intrinsic value of $91 per share. We cut our 2026 EPS estimate by $0.47 to $2.48, but we raise 2027's by $0.07 to $3.24. We acknowledge that the oilfield services business is likely to struggle in 2026 owing to the U.S.-Iran conflict, but the IET business appears quite robust and likely to be a source of both accelerating revenue growth and margins.
Research Alert: CFRA Maintains Hold Opinion In Shares Of Wab
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $285 from $275 following WAB's Q1 earnings print, valuing shares at 24.2x our 2027 EPS outlook of $11.76 (revised from $11.46; 2026 EPS estimate up to $10.57 from $10.50), a slight premium to WAB's long-term historical multiple average given structural improvements in earnings quality. While we are cautious on signs of overcapacity in the freight market, an elevated order backlog (12-month sits at over $9 billion), internal initiatives to shore up margins, and potential synergies from M&A activity positions WAB to continue growing earnings at double-digit rates in 2026-2027, in our view. Despite tariff-related cost pressures, WAB has done a commendable job of defending margins via a mix of pricing, lean manufacturing, and pruning of lower-profit operations. Q1 results were mixed but overall positive, in our view. We maintain our Hold recommendation on shares.